Author

J.R. Hecht

Observed name: J. R. Hecht

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Observed institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

ORCID: 0000-0003-2277-4157

Observed ORCID: 0000-0003-2277-4157

OpenAlex ID: A5074574486

340O Safety and efficacy of zoldonrasib (RMC-9805) plus chemotherapy in patients (pts) with 1L RAS G12D metastatic pancreatic adenocarcinoma (MPDAC)

2026 · B.M. Wolpin, S. Pant, et al. · Annals of Oncology · 6

514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

2024 · B. Wolpin, D. Hong, et al. · European Journal of Cancer · 5

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)

2022 · C.K. Kyi, A. Spira, et al. · Annals of Oncology · 5

LBA1 Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial

2026 · J. Tabernero, S. Kopetz, et al. · Annals of Oncology · 1

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

2026 · M. Fakih, S. Gill, et al. · ESMO Gastrointestinal Oncology · 1

Abstract PS5-08-03: Denali-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with triple-negative breast cancer and other EGFR-expressing solid tumors with HLA-A*02 loss of heterozygosity (LOH)

2026 · J. M. Specht, S. R. Punekar, et al. · Clinical Cancer Research · 1

439TiP A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

2022 · M.G. Fakih, M. Tejani, et al. · Annals of Oncology · 1

1558P Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFR×CD28 bispecific antibody (bsAb)

2025 · N.H. Segal, E. Girda, et al. · Annals of Oncology

Results from the LOGiC Trial

2013 · M. B. Nierengarten, J. R. Hecht · MD Conference Express

Works count: 9

Citation count: 19

H-index: 3

I10-index: